ABSTRACT
PURPOSE: To clarify the diagnostic utility and formation of the Mille-feuille sign for ovarian carcinosarcoma (OCS) on MRI, and to evaluate the other MRI findings and serum markers compared to ovarian metastases from colorectal carcinoma (OMCRC). METHOD: Three blinded radiologists retrospectively reviewed MR images of 12 patients with OCS, 18 with OMCRC, and 40 with primary ovarian carcinoma (POC) identified by the electronic database of radiology reports. The interobserver agreement was analyzed using Fleiss' kappa test. Their MRI characteristics and tumor markers were compared using Fisher's exact test and Mann-Whitney's U test. Receiver operating characteristic curve analyses were used to determine the cutoff points for the ADC value. This study was approved by the institutional ethics committee. RESULTS: Interobserver agreement analysis was moderate or higher for all MRI characteristics. The frequency of Mille-feuille sign was comparable for both OCS and OMCRC groups, and predominantly higher than that of the POC group (p < 0.001, p < 0.001), respectively. Pathologically, the Mille-feuille sign in OCS reflected alternating layers of tumor cells with stroma and necrosis or intraluminal necrotic debris. Compared to OMCRC, intratumoral hemorrhage (p = 0.02), margin irregularity (p = 0.048), unilateral adnexal mass (p = 0.02), and low ADC values (p < 0.01) were more frequently observed and serum CEA levels was significantly lower (p = 0.007) in the OCS group. Under setting of the cutoff value of ADC at 0.871 × 10-3mm2/s, the discriminative ability for OCS showed 66.7% sensitivity, 94.4% specificity, and 81.0% accuracy, respectively. CONCLUSIONS: The Mille-feuille sign was seen in both OCS and OMCRC. MR findings of intratumoral hemorrhage, margin irregularity, unilateral adnexal mass, low ADC values, and low serum CEA levels can be useful in differentiating OCS from OMCRC.
Subject(s)
Carcinosarcoma , Colorectal Neoplasms , Magnetic Resonance Imaging , Ovarian Neoplasms , Humans , Female , Middle Aged , Carcinosarcoma/diagnostic imaging , Carcinosarcoma/secondary , Retrospective Studies , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/pathology , Aged , Magnetic Resonance Imaging/methods , Colorectal Neoplasms/pathology , Colorectal Neoplasms/diagnostic imaging , Adult , Diagnosis, Differential , Aged, 80 and over , Biomarkers, Tumor/blood , Sensitivity and Specificity , Contrast MediaABSTRACT
OBJECTIVE: Utilization of neoadjuvant chemotherapy (NACT) for advanced stage uterine cancer is increasing. We analyzed the use and outcomes of open versus minimally invasive surgery (MIS) for women with stage IV uterine cancer who received NACT and underwent IDS. METHODS: The National Cancer Database was used to identify women with stage IV uterine cancer diagnosed from 2010 to 2017 and treated with NACT. Among women who underwent IDS, overall survival (OS) was compared between those who underwent laparotomy vs a minimally invasive approach. To account for imbalances in confounders, a propensity score analysis using inverse probability of treatment weighting (IPTW) was performed. RESULTS: A total of 1618 women were identified. Minimally invasive IDS was performed in 31.1% and increased from 16.2% in 2010 to 40.4% in 2017 (P < 0.001). More recent year of diagnosis and performance of surgery at a comprehensive cancer center were associated with increased use of MIS (P < 0.05). Women with serous and clear cell tumors, and carcinosarcomas (compared to endometrioid tumors), as well as Medicaid coverage (compared to commercial insurance) were less likely to undergo an MIS approach (P < 0.05). The median OS was 28 months (95% CI 23.7-30.7) and 24.3 months (95% CI 22.3-26.1) for MIS and laparotomy, respectively. After propensity score balancing, there was no association between the use of MIS and survival (HR = 0.90, 95% CI 0.71-1.14). CONCLUSIONS: Among women with stage IV uterine cancer treated with NACT performance of minimally invasive debulking surgery is increasing. Compared to laparotomy, MIS does not appear to negatively impact survival.
Subject(s)
Carcinoma, Endometrioid/surgery , Carcinosarcoma/surgery , Cytoreduction Surgical Procedures/methods , Hysterectomy/methods , Minimally Invasive Surgical Procedures/methods , Neoadjuvant Therapy , Neoplasms, Cystic, Mucinous, and Serous/surgery , Uterine Neoplasms/surgery , Aged , Carcinoma, Endometrioid/secondary , Carcinosarcoma/secondary , Cytoreduction Surgical Procedures/trends , Female , Humans , Hysterectomy/trends , Insurance, Health/statistics & numerical data , Laparotomy , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Neoplasms, Cystic, Mucinous, and Serous/secondary , Uterine Neoplasms/pathologyABSTRACT
Uterine carcinosarcoma (UCS) is a malignant tumor with a high tendency to invasion and metastasis. However, the underlying invasion and metastasis mechanisms of UCS remain poorly understood. Genetic alteration and tumor-infiltrating immune cells play important roles in tumorigenesis, progression, and metastasis. To better understand the underlying mechanisms of UCS, we screened tumor-infiltrating immune cells by applying CIBERSORT algorithm and constructed nomograms to predict the prognosis of UCS patients based on metastasis-specific tumor-infiltrating immune cells and genes, and demonstrated their utility by the high AUC values. Combining gene co-expression and experimental validation results, we propose a potential mechanism of AK8, MPZ, and mast cells activated might play important parts in UCS metastasis.
Subject(s)
Biomarkers, Tumor/genetics , Carcinosarcoma/genetics , Carcinosarcoma/immunology , Decision Support Techniques , Nomograms , Tumor Microenvironment/immunology , Uterine Neoplasms/genetics , Uterine Neoplasms/immunology , Adenylate Kinase/genetics , Adenylate Kinase/metabolism , Aged , Aged, 80 and over , Carcinosarcoma/metabolism , Carcinosarcoma/secondary , Cell Movement , Databases, Genetic , Female , Gene Expression Regulation, Neoplastic , Humans , Mast Cells/immunology , Middle Aged , Myelin P0 Protein/metabolism , Neoplasm Invasiveness , Predictive Value of Tests , Prognosis , Reproducibility of Results , Tumor Cells, Cultured , Uterine Neoplasms/metabolism , Uterine Neoplasms/pathologySubject(s)
Carcinosarcoma/surgery , Radiofrequency Ablation/methods , Retroperitoneal Neoplasms/surgery , Surgery, Computer-Assisted/methods , Tomography, X-Ray Computed , Uterine Neoplasms/surgery , Carcinosarcoma/diagnostic imaging , Carcinosarcoma/secondary , Female , Humans , Medical Illustration , Middle Aged , Retroperitoneal Neoplasms/diagnostic imaging , Retroperitoneal Neoplasms/secondary , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/pathologyABSTRACT
BACKGROUND: Uterine carcinosarcomas (UCS) are rare tumors that carry a poor prognosis and high recurrence rate. Standard treatment consists of surgical resection and chemotherapy, though the benefit of adjuvant radiotherapy (RT) has yet to be determined. This study assessed survival rates between patients with UCS who underwent surgical resection alone and patients who underwent combinations of surgery, chemotherapy, and RT. MATERIALS AND METHODS: We conducted a retrospective review of all patients who underwent surgical resection for UCS between 1993 and 2011 at a single institution. We assessed 3-year disease-free survival, locoregional recurrence-free survival, distant metastases-free survival (DMFS), and overall survival rates and utilized Kaplan-Meier modeling to analyze differences between UCS treatment modalities. RESULTS: Twenty-four patients underwent UCS surgical resection between 1993 and 2011. The mean age was 61 (range: 39 to 75 y). Of these patients, 100% (n=24) underwent surgical resection, 25% (n=6) underwent surgery and adjuvant chemotherapy, 29% (n=7) underwent surgery and adjuvant RT, and 33% (n=8) underwent surgery and adjuvant chemotherapy and RT. At 3 years median follow, there was no significant difference in overall survival between treatment modalities. The addition of radiation therapy conferred increased DMFS in patients undergoing surgery irrespective of adjuvant chemotherapy (44% vs. 83%, P=0.0211).In patients receiving adjuvant chemotherapy, the significant increase in DMFS persisted with the addition of RT (P=0.0310). Lymph node involvement (n=8) was associated with a lower locoregional recurrence-free survival (38% vs. 92%, P=0.0029). CONCLUSIONS: RT may offer a potential benefit in reducing the rate of distant metastases, though there were no statistically significant improvements in survival metrics.
Subject(s)
Carcinosarcoma/secondary , Pelvis/radiation effects , Radiotherapy, Adjuvant , Radiotherapy, Conformal , Uterine Neoplasms/radiotherapy , Adult , Aged , Carcinosarcoma/drug therapy , Carcinosarcoma/radiotherapy , Carcinosarcoma/surgery , Chemotherapy, Adjuvant , Combined Modality Therapy , Disease-Free Survival , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Lymphatic Metastasis , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Retrospective Studies , Uterine Neoplasms/drug therapy , Uterine Neoplasms/surgeryABSTRACT
Intramedullary spinal cord metastases (ISCM) is a rare, but devastating complication of malignant disease. Prognosis is poor, with an overall median survival (OS) of 4 months from the time of diagnosis. Yet, ISCMs are being increasingly diagnosed, related to advances and increased use of imaging and therapies that prolong survival in patients with cancer. Prompt and accurate diagnosis of ISCM is necessary for effective treatment, and magnetic resonance imaging (MRI) is the preferred imaging technique. The optimal management of these patients is controversial because of the multitude of clinical circumstances and the lack of controlled studies on the efficacy of the different therapeutic approaches. Increased awareness of this rare entity may lead to an earlier diagnosis at a stage when neurological deficits are reversible, and therefore, more effective palliation may be achieved. Therefore, we carried out this retrospective research of 3 observations of ISCM, associated with a detailed review of the literature describing the diagnostic, therapeutic and evolutionary characteristics of this special rare entity.
Subject(s)
Adenocarcinoma/secondary , Carcinosarcoma/secondary , Rare Diseases/etiology , Spinal Cord Neoplasms/secondary , Adenocarcinoma/complications , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/therapy , Adult , Breast Neoplasms/pathology , Carcinosarcoma/complications , Carcinosarcoma/diagnostic imaging , Carcinosarcoma/therapy , Early Detection of Cancer , Fatal Outcome , Female , Humans , Lumbar Vertebrae , Lung Neoplasms/pathology , Magnetic Resonance Imaging , Male , Middle Aged , Rare Diseases/diagnostic imaging , Rare Diseases/therapy , Retrospective Studies , Spinal Cord Neoplasms/complications , Spinal Cord Neoplasms/diagnostic imaging , Spinal Cord Neoplasms/therapy , Thoracic VertebraeABSTRACT
BACKGROUND: Cutaneous carcinosarcoma is a rare biphasic tumor comprising malignant epithelial and heterologous mesenchymal elements. Data on the clinical and histopathologic characteristics of this tumor are scarce. The objective of this study was to describe the clinicopathologic and immunohistochemical features of cutaneous carcinosarcoma. METHODS: A descriptive retrospective study was conducted in a tertiary care hospital from Spain. We reviewed the records of eight patients with cutaneous carcinosarcoma who were diagnosed from 2009 to 2019. RESULTS: The mean patient age at diagnosis was 72.13 years (range 44-91 years), and there was a male predilection (6 cases). The most common site of cutaneous carcinosarcoma was the head and neck (5 cases). Carcinosarcomas demonstrated variable histopathological and immunohistochemical features. Follow-up was available for 7-8 patients. There were two cases of local recurrence and one case of metastasis. Two patients died from the tumor during the entire follow-up. CONCLUSIONS: Although the number of cases in this study was limited, our results provide valuable insight into the clinical, histopathologic, and immunohistochemical characteristics of primary cutaneous carcinosarcoma.
Subject(s)
Carcinosarcoma/metabolism , Carcinosarcoma/pathology , Neoplasm Recurrence, Local/pathology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Actins/metabolism , Adult , Aged, 80 and over , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Carcinosarcoma/secondary , Carcinosarcoma/surgery , Desmin/metabolism , Female , Humans , Immunohistochemistry , Keratin-1/metabolism , Keratin-3/metabolism , Male , Matrix Attachment Region Binding Proteins/metabolism , Membrane Proteins/metabolism , Middle Aged , Myogenin/metabolism , Neprilysin/metabolism , Retrospective Studies , Skin Neoplasms/surgery , Transcription Factors/metabolism , alpha 1-Antitrypsin/metabolismABSTRACT
BACKGROUND: Brain metastases from endometrial cancer are rare and poorly described. We aimed to estimate the proportion of brain metastases at our institution that arose from endometrial cancer, and to detail clinicopathologic features and survival outcomes. METHODS: We retrospectively identified and reviewed the charts of 30 patients with brain metastases from endometrial cancer seen at Stanford Hospital from 2008 to 2018. RESULTS: Among all patients with brain metastases, the proportion arising from endometrial cancer was 0.84%. The median age at diagnosis was 62 years (range, 39-79 years), and the median overall survival from brain metastasis diagnosis was 6.8 months (range, 1.0-58.2 months). Most patients harbored endometrioid histology (53.3%), and some had concurrent metastases to lung (50.0%), bone (36.7%), and liver (20.0%). The median time from endometrial cancer diagnosis to brain metastasis development was 20.8 months (range, 1.4 months to 11.2 years), and the median number of brain metastases was 2 (range, 1-20). Patients with non-endometrioid histologies had more brain metastases than those with endometrioid histology (6.21 vs. 2.44, P = 0.029). There was no difference in overall survival by histology. CONCLUSIONS: We describe the largest cohort to date of patients with brain metastases originating from endometrial cancer. These patients represent a small fraction of all patients with brain metastases and have poor prognoses. These data enable providers caring for patients with brain metastases from endometrial cancer to appropriately counsel their patients.
Subject(s)
Brain Neoplasms/secondary , Carcinoma, Endometrioid/secondary , Carcinosarcoma/secondary , Endometrial Neoplasms/pathology , Neoplasms, Cystic, Mucinous, and Serous/secondary , Adult , Aged , Asymptomatic Diseases , Ataxia/physiopathology , Bone Neoplasms/secondary , Brain Neoplasms/physiopathology , Brain Neoplasms/therapy , Carcinoma, Endometrioid/physiopathology , Carcinoma, Endometrioid/therapy , Carcinosarcoma/physiopathology , Carcinosarcoma/therapy , Cranial Nerve Diseases/physiopathology , Female , Headache/physiopathology , Humans , Karnofsky Performance Status , Liver Neoplasms/secondary , Lung Neoplasms/secondary , Metastasectomy , Middle Aged , Muscle Weakness/physiopathology , Neoplasm Grading , Neoplasms, Cystic, Mucinous, and Serous/physiopathology , Neoplasms, Cystic, Mucinous, and Serous/therapy , Neurosurgical Procedures , Radiosurgery , Survival Rate , Time FactorsABSTRACT
BACKGROUND: Pancreatic carcinosarcomas (PCS) are rare aggressive biphasic malignancies with a poor prognosis. We aimed to improve the understanding of PCS by analyzing variables that influence the mortality of PCS patients. METHODS: The Surveillance, Epidemiology, and End Results database was queried for cases of PCS from 1973 to 2016. Cases were analyzed for patient demographics, tumor characteristics, and surgical intervention. Kaplan-Meier and Cox regression analyses were applied to investigate the overall survival (OS) and prognostic factors. RESULTS: Thirty-nine cases of PCS were identified along with the disease demographics and characteristics. The majority of patients had a regionally invasive or metastatic disease. There was a significant decrease in OS with the increase of the tumor extension. Conversely, surgery showed to improve OS in the crude analysis, including patients that underwent lymphadenectomy. In addition, the unadjusted Cox regression results showed decreased hazard ratios with a local disease versus distant metastasis and with cancer-directed surgery versus no surgery. Nevertheless, the adjusted Cox regression results revealed that metastatic disease was the only significant predictor of survival. CONCLUSIONS: This population-based study provides some insight to a very rare disease by analyzing 39 cases of PCS. Our finding suggests considering PCS as a nonsurgical disease and reserving surgery solely for patients with a localized disease in combination or after neoadjuvant therapy. Consequently, there is a need to further investigate novel therapies for this aggressive malignancy.
Subject(s)
Carcinosarcoma/mortality , Neoadjuvant Therapy/statistics & numerical data , Pancreatectomy/statistics & numerical data , Pancreatic Neoplasms/mortality , Aged , Carcinosarcoma/secondary , Carcinosarcoma/therapy , Chemotherapy, Adjuvant/statistics & numerical data , Databases, Factual/statistics & numerical data , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Neoadjuvant Therapy/methods , Neoplasm Invasiveness , Pancreas/pathology , Pancreas/surgery , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/therapy , Prognosis , Retrospective Studies , Risk Factors , SEER Program/statistics & numerical data , Treatment Outcome , United States/epidemiologyABSTRACT
OBJECTIVE: To examine the survival of women with stage I non-endometrioid endometrial cancer with malignant peritoneal cytology. METHODS: A retrospective observational cohort study was conducted to examine the National Cancer Institute's Surveillance, Epidemiology, and End Results Program from 2010 to 2016. Women with stage I serous, clear cell, carcinosarcoma, undifferentiated, and mixed endometrial cancer with known peritoneal cytology results at hysterectomy were examined (N = 4506). Propensity score inverse probability of treatment weighting was used to balance the measured covariates, and survival outcomes were assessed according to peritoneal cytology results. RESULTS: Malignant peritoneal cytology was reported in 401 (8.9%) women. In multivariable analysis, older age, serous histology, and large tumors were associated with an increased likelihood of malignant peritoneal cytology (all, P < 0.05). In a propensity score weighted model, malignant peritoneal cytology was associated with a nearly two-fold increase in all-cause mortality risk compared to negative peritoneal cytology (5-year rates, 63.4% versus 80.2%, hazard ratio 2.18, 95% confidence interval 1.78-2.66). In sensitivity analyses, malignant peritoneal cytology was associated with decreased overall survival in old and young age groups, serous, clear cell, carcinosarcoma, and mixed histology groups, stage T1a disease, and staged and unstaged cases, but not for stage T1b disease. Difference in 5-year overall survival rates between the malignant and negative peritoneal cytology groups was particularly large among those with clear cell histology (24.0%), stage T1a disease (19.4%), aged >78 years (18.2%), and serous tumors (17.6%). CONCLUSION: Malignant peritoneal cytology can be prevalent in stage I non-endometrioid endometrial cancer. Our study suggests that malignant peritoneal cytology is a prognostic factor for decreased survival in stage I non-endometrioid endometrial cancer.
Subject(s)
Adenocarcinoma, Clear Cell/epidemiology , Carcinosarcoma/epidemiology , Cystadenocarcinoma, Serous/epidemiology , Endometrial Neoplasms/pathology , Peritoneum/pathology , Adenocarcinoma, Clear Cell/diagnosis , Adenocarcinoma, Clear Cell/secondary , Age Factors , Aged , Carcinosarcoma/diagnosis , Carcinosarcoma/secondary , Chemotherapy, Adjuvant , Cystadenocarcinoma, Serous/diagnosis , Cystadenocarcinoma, Serous/secondary , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/mortality , Endometrial Neoplasms/therapy , Female , Humans , Hysterectomy , Middle Aged , Neoplasm Staging , Prevalence , Prognosis , Retrospective Studies , Risk Assessment/statistics & numerical data , Risk Factors , SEER Program/statistics & numerical data , Survival Rate , Treatment Outcome , United States/epidemiologyABSTRACT
PURPOSE: The relevance of the MET/hepatocyte growth factor pathway in endometrial cancer tumor biology supports the clinical evaluation of cabozantinib in this disease. PATIENTS AND METHODS: PHL86/NCI#9322 (NCT01935934) is a single arm study that evaluated cabozantinib (60 mg once daily) in women with endometrial cancer with progression after chemotherapy. Coprimary endpoints were response rate and 12-week progression-free-survival (PFS). Patients with uncommon histology endometrial cancer (eg, carcinosarcoma and clear cell) were enrolled in a parallel exploratory cohort. RESULTS: A total of 102 patients were accrued. Among 36 endometrioid histology patients, response rate was 14%, 12-week PFS rate was 67%, and median PFS was 4.8 months. In serous cohort of 34 patients, response rate was 12%, 12-week PFS was 56%, and median PFS was 4.0 months. In a separate cohort of 32 patients with uncommon histology endometrial cancer (including carcinosarcoma), response rate was 6% and 12-week PFS was 47%. Six patients were on treatment for >12 months, including two for >30 months. Common cabozantinib-related toxicities (>30% patients) included hypertension, fatigue, diarrhea, nausea, and hand-foot syndrome. Gastrointestinal fistula/perforation occurred in four of 70 (6%) patients with serous/endometrioid cancer and five of 32 (16%) patients in exploratory cohort. We observed increased frequency of responses with somatic CTNNB1 mutation [four partial responses (PRs) in 10 patients, median PFS 7.6 months] and concurrent KRAS and PTEN/PIK3CA mutations (three PRs in 12 patients, median PFS 5.9 months). CONCLUSIONS: Cabozantinib has activity in serous and endometrioid histology endometrial cancer. These results support further evaluation in genomically characterized patient cohorts.
Subject(s)
Anilides/therapeutic use , Carcinosarcoma/drug therapy , Endometrial Neoplasms/drug therapy , Neoplasm Recurrence, Local/drug therapy , Pyridines/therapeutic use , Adult , Aged , Aged, 80 and over , California , Carcinosarcoma/secondary , Cohort Studies , Endometrial Neoplasms/pathology , Female , Follow-Up Studies , Humans , Middle Aged , Neoplasm Recurrence, Local/pathology , Prognosis , Survival RateABSTRACT
BACKGROUND: Triple-negative breast cancer (TNBC) is one of the most invasive subtypes of breast cancer, with high rates of visceral metastases and recurrence. Choroid plexus metastasis from breast cancer is infrequent despite a high incidence of brain parenchymal metastasis. METHODS: We report a case of solitary metastasis to the choroid plexus from a TNBC that masqueraded as central neurocytoma, and we review the PubMed database for similar cases focusing on their diagnostic challenges and management strategies. RESULTS: A 28-year-old woman with a history of TNBC presented with recurrent seizures, headache, and vomiting. Imaging studies depicted a well-defined lesion in the right anterior lateral ventricle that was attached to the septum pellucidum. After an initial radiological diagnosis of central neurocytoma, she deteriorated rapidly with intraventricular hemorrhage requiring emergency transcallosal microsurgical tumor decompression. Histopathological examination and immunohistochemistry confirmed breast carcinoma as the origin of the intraventricular mass. A review of the PubMed database identified only 2 case reports of choroid plexus metastases from breast cancer reported thus far. CONCLUSIONS: Choroid plexus metastases are exceedingly infrequent and can be mistaken for the more common central neurocytoma. The intraventricular milieu is inhospitable suggesting some extracranial carcinomas develop traits that help them to thrive in the acellular cerebrospinal fluid. Intraventricular mass lesions with a history of primary neoplasm should raise suspicion for choroid plexus metastases. A high index of suspicion despite excellent control of the primary tumor and the absence of systemic metastases is indispensable.
Subject(s)
Carcinosarcoma/diagnostic imaging , Choroid Plexus Neoplasms/diagnostic imaging , Neurocytoma/diagnosis , Triple Negative Breast Neoplasms/pathology , Adult , Carcinosarcoma/secondary , Carcinosarcoma/surgery , Choroid Plexus Neoplasms/secondary , Choroid Plexus Neoplasms/surgery , Diagnosis, Differential , Female , HumansABSTRACT
OBJECTIVES: To evaluate the prognostic impact of aortic vs. pelvic lymph node (LN) metastasis among women with endometrial cancer (EC). METHODS: Using data from the SEER 18 Registries we identified 3650 women with LN positive (stage IIIC) EC. We used Kaplan-Meier curves and log-rank tests to compare mortality between women with stage IIIC1 and IIIC2 disease. We used Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between stage III sub-stage (IIIC1 vs. IIIC2) and survival. RESULTS: Endometrioid tumors were more common among women with stage IIIC1 than IIIC2 tumors (62.5% vs. 54.3%) while, non-endometrioid histologies were more common among stage IIIC2. In the multivariable model, stage IIIC2 was associated with higher all-cause (HRâ¯=â¯1.44, 95% CIâ¯=â¯1.22-1.69) and EC-specific mortality (HRâ¯=â¯1.49, 95% CIâ¯=â¯1.25-1.77) compared with IIIC1. Women with non-endometrioid EC had poor survival, in particular, women with carcinosarcomas had higher EC-specific mortality compared to women with endometrioid EC (HRâ¯=â¯3.32, 95% CIâ¯=â¯2.71-4.07). When stratifying women according to substage, older age and non-endometrioid histology were associated with higher EC-specific mortality. Compared to women with a pelvic-only LN dissection, women with pelvic and aortic dissections had lower all-cause (HRâ¯=â¯0.74, 95% CIâ¯=â¯0.63-0.88) and EC-specific (HRâ¯=â¯0.79, 95% CIâ¯=â¯0.66-0.95) mortality. CONCLUSION: Women with aortic LN positive EC are more likely to die from their disease. Older women and non-endometrioid histologies are more likely to have aortic LN involvement. Compared to women with a pelvic-only LN dissection, women with pelvic and aortic dissections had lower EC mortality.
Subject(s)
Carcinoma, Endometrioid/secondary , Carcinosarcoma/secondary , Endometrial Neoplasms/mortality , Endometrial Neoplasms/pathology , Lymph Nodes/pathology , Adolescent , Adult , Age Factors , Aged , Aorta , Carcinoma, Endometrioid/mortality , Carcinoma, Endometrioid/surgery , Carcinosarcoma/mortality , Endometrial Neoplasms/surgery , Female , Humans , Kaplan-Meier Estimate , Lymph Node Excision , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Pelvis , Prognosis , Proportional Hazards Models , SEER Program , Survival Rate , United States/epidemiology , Young AdultABSTRACT
Background. Ovarian carcinosarcomas are rare aggressive biphasic tumors. Evidence suggests that these tumors are monoclonal and that the sarcoma component is derived from a stem cell undergoing divergent differentiation. Currently, there remains a paucity of data regarding its origin, with few reports suggesting an association with serous tubal intraepithelial carcinoma (STIC) by immunohistochemistry and genetics. Objective. We sought to determine the relationship of carcinosarcoma to high-grade serous carcinoma and STIC by investigating for similar mutation signatures through next-generation sequencing. Methodology. A case of carcinosarcoma with associated high-grade serous carcinoma and STIC was macrodissected, and next-generation sequencing was performed on each component separately. Results. The STIC, high-grade serous carcinoma component, and chondrosarcoma component were all diffusely positive for p53 and p16 by immunohistochemistry. Next-generation sequencing demonstrated an identical TP53 gene c.376-1G>A 5' splice site pathogenic mutation in all 3 components. Conclusions. Our findings suggest that carcinosarcomas may also originate from the fallopian tube.
Subject(s)
Carcinosarcoma/genetics , Cystadenocarcinoma, Serous/genetics , Fallopian Tube Neoplasms/pathology , Mixed Tumor, Mullerian/genetics , Ovarian Neoplasms/genetics , Aged , Carcinosarcoma/diagnosis , Carcinosarcoma/secondary , Cyclin-Dependent Kinase Inhibitor p16/genetics , Cystadenocarcinoma, Serous/diagnosis , Cystadenocarcinoma, Serous/secondary , DNA Mutational Analysis , Fallopian Tube Neoplasms/diagnosis , Fallopian Tube Neoplasms/genetics , Female , High-Throughput Nucleotide Sequencing , Humans , Mixed Tumor, Mullerian/diagnosis , Mixed Tumor, Mullerian/secondary , Mutation , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/secondary , Tumor Suppressor Protein p53/geneticsSubject(s)
Carcinosarcoma/secondary , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Skin Neoplasms/secondary , Skin Neoplasms/surgery , Aged, 80 and over , Biopsy, Needle , Carcinosarcoma/pathology , Carcinosarcoma/surgery , Humans , Immunohistochemistry , Japan , Male , Prognosis , Rare Diseases , Skin Neoplasms/pathology , Thoracic Surgery, Video-Assisted/methods , Treatment OutcomeABSTRACT
OBJECTIVES: To evaluate the clinical outcomes of epithelial ovarian carcinoma patients who underwent cardiophrenic lymph node resection. METHODS: We retrospectively reviewed the records of all surgically treated patients with advanced epithelial ovarian carcinoma (stages IIIC-IV) who underwent cardiophrenic lymph node resection between 2002 and 2018. Only those in whom cardiophrenic lymph node involvement was the only detectable extra-abdominal disease were included. Patients with suspected cardiophrenic lymph node metastasis on staging images underwent a transdiaphragmatic incision to access the para-cardiac space after complete abdominal cytoreduction achievement. Data on disease-free survival, overall survival, and surgical procedures performed concurrently with cardiophrenic lymph node resection were collected. RESULTS: Of the total 456 patients, 29 underwent cardiophrenic lymph node resection; of these, 24 patients met the inclusion criteria. Twenty-two, one, and one patients had high grade serous epithelial ovarian carcinoma, low grade epithelial ovarian carcinoma, and ovarian carcinosarcoma, respectively. Ten patients had recurrent disease (recurrence group). Fourteen patients underwent cytoreduction during primary treatment (primary debulking group); four underwent cytoreduction after neoadjuvant chemotherapy. Cardiophrenic lymph node resection was performed on the right side in 19 patients, left side in three, and bilaterally in two. The average procedural duration was 28 minutes, with minimal blood loss and no severe complications. Twenty-one patients had cardiophrenic lymph node positivity. The median disease-free intervals were 17 and 12 months in the recurrent and primary debulking surgery groups, respectively. The mediastinum was the first recurrence site in 10 patients. Five patients developed brain metastases. Five patients had an overall survival beyond 50 months. CONCLUSIONS: Although rare, the cardiophrenic lymph nodes may be a site of metastasis of ovarian cancer. Although their presence might indicate future recurrence, some patients may achieve long-term survival. Resection should be considered in cases of suspicious involvement to confirm extra-abdominal disease and achieve complete cytoreduction.
Subject(s)
Cytoreduction Surgical Procedures/mortality , Lymph Node Excision/mortality , Lymph Nodes/surgery , Neoplasm Recurrence, Local/surgery , Ovarian Neoplasms/surgery , Pericardium/surgery , Adult , Aged , Carcinosarcoma/secondary , Carcinosarcoma/surgery , Cystadenocarcinoma, Serous/secondary , Cystadenocarcinoma, Serous/surgery , Diaphragm , Female , Follow-Up Studies , Humans , Lymph Nodes/pathology , Lymphatic Metastasis , Middle Aged , Neoplasm Recurrence, Local/pathology , Ovarian Neoplasms/pathology , Pericardium/pathology , Prognosis , Retrospective Studies , Survival RateABSTRACT
Mixed carcinomas in the esophagus are highly uncommon neoplasms that represent a diagnostic challenge on small tissue biopsies. We present a case of a primary mixed sarcomatoid-small cell carcinoma of the esophagus that was diagnosed after repeat sampling of the lesion. The components were morphologically distinct and could be further classified by immunohistochemistry. Next-generation sequencing identified mutations in PIK3CA and CDKN2A. The small cell component morphology was also identified in brain metastasis.
Subject(s)
Brain Neoplasms/secondary , Carcinoma, Small Cell/secondary , Carcinosarcoma/secondary , Esophageal Neoplasms/pathology , Neoplasms, Complex and Mixed/pathology , Carcinoma, Neuroendocrine/genetics , Carcinoma, Neuroendocrine/secondary , Carcinoma, Small Cell/genetics , Class I Phosphatidylinositol 3-Kinases/genetics , Cyclin-Dependent Kinase Inhibitor p16/genetics , Esophageal Neoplasms/genetics , Female , Humans , Middle Aged , Mutation , Neoplasms, Complex and Mixed/geneticsABSTRACT
We present the case of a 44-year-old man diagnosed with metastatic sarcomatoid carcinoma of the prostate. The pathogenesis and optimal treatment of this rare and aggressive subtype of prostate cancer are not fully clear. The patient was managed using a multimodality approach of chemotherapy, hormonal blockade and radiation therapy, with palliative intent.
Subject(s)
Carcinosarcoma/diagnosis , Carcinosarcoma/therapy , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/therapy , Adult , Biopsy , Carcinosarcoma/pathology , Carcinosarcoma/secondary , Combined Modality Therapy , Docetaxel/administration & dosage , Heart Neoplasms/secondary , Heart Ventricles , Humans , Magnetic Resonance Imaging , Male , Palliative Care , Pleural Effusion, Malignant/surgery , Prostatic Neoplasms/pathology , Radiotherapy , Thoracic Surgery, Video-Assisted , Tomography, X-Ray ComputedABSTRACT
Therapeutic agents targeting the PD-1/PD-L1 axis have shown durable clinical responses in patients with various cancer types. Although objective responses are common, intrapatient heterogeneous responses have been described, and the mechanism for the different organ responses remains unknown. We present a series of patients in whom a lack of response was noted solely in the adrenal glands. This is the first case series describing 3 patients with heterogeneous patterns of response to pembrolizumab with progression of adrenal metastatic disease despite objective response (complete or partial response) in all other sites of metastatic disease. Two patients, one with melanoma and one with uterine carcinosarcoma, underwent robotic adrenalectomy for enlarging adrenal metastases. An additional patient with melanoma underwent laparotomy with attempted resection, but infiltration of the adrenal tumor into the inferior vena cava prohibited safe excision. This report provides additional insight into the heterogeneous patterns of disease response to anti-PD-1 therapy, highlighting the adrenal gland as a potential sanctuary site for this immunotherapy. These cases display the potential benefit of early surgical resection in this scenario and the pitfalls of delaying referral to a surgeon for assessment of operative intervention.